The week in pharma: action, reaction and insight – week to March 4, 2022
By Barbara Obstoj-Cardwell. Editor
India’s Biocon announced a $3.3 billion deal to acquire the recently set up generics powerhouse Viatris’ biosimilars assets. US pharma giant Pfizer became the latest to hit a roadblock in its attempts to develop a Clostridioides difficile vaccine, (PF-06425090), reporting mixed results from a Phase III trial. Meantime, AstraZeneca and Sanofi presented positive new Phase III data on their RSV disease candidate nirsevimab last Wednesday. Also, drug developer Karyopharm suffered a setback with its endometrial p53 wild-type candidate Xpovio (selinexor).
Another biosimilars retreat, this time from Viatris
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze